Zanubrutinib for Waldenström macroglobulinaemia: predicted versus actual analysis
Page last updated: 10 October 2025
Drug utilisation sub-committee (DUSC)
April 2025
Abstract
Purpose
To compare the predicted and actual utilisation of zanubrutinib for the treatment of Waldenström macroglobulinaemia (WM) in treatment-naïve (first line) patients who are unsuitable for chemo-immunotherapy and for relapsed/refractory (second and subsequent lines) patients who have received at least one prior therapy since zanubrutinib’s listing on the Pharmaceutical Benefits Scheme (PBS).
Date of listing on the Pharmaceutical Benefits Scheme (PBS)
Zanubrutinib was first listed on the PBS for WM on 1 July 2022.
Data Source / methodology
Authorities data and prescriptions data were extracted from the prescription database and
Authorities database maintained by the Department of Health, Disability and Ageing, processed by Services Australia from between 1 July 2022 and 30 June 2024, respectively. Data were extracted based on the date of supply.
Key Findings
- Actual patient numbers were different than predicted over the first two years of listing.
- Actual script numbers were different than predicted over the first two years of listing.
- Actual script numbers per patient were different than predicted over the first two years of listing.
